Company Release

Nanoform Finland Plc

April 26, 2024

11.00 Finnish time / 10.00 Swedish time

Disclosure of Major Holdings under Law 163/2024

Nanoform Finland Plc ("Nanoform" or the "Company") has on April 25, 2024, received a notification from Mandatum Oyj. The notification was made pursuant to law 163/2024 amending the Finnish Securities Market Act (the "Act"). Under the transition rules of the Act, a shareholder in a First North listed company is in required to notify major holdings within two months from the entry into force of the Act. The notification has been made on the basis of the transition rules of the Act, and not an acquisition or disposal of shares.

Nanoform has one series of shares in which each share carries one vote. The percentage numbers indicate the shareholding on the date the Act entered into force on April 19, 2024. The aggregate number of shares at the entry into force of the Act was 78,445,164.

Total positions
of Mandatum Oyj
subject to the
notification
obligation:
% of % of shares Total Total number of
shares and voting of shares and
and rights both voting
voting through in % rights of issue
rights financial (7.A + (on April 19,
(total instruments 7.B) 2024)
of 7.A) (total of 7.B)
Resulting 6.56 % 0 6.56 % 78,445,164
situation on the
date on
which threshold
was crossed or
reached
Position of Click Click here to Click
previous here to enter text. here
notification enter to
(if applicable) text. enter
text.

Notified
details of the
resulting
situation on
the date on
which the
threshold was
crossed or
reached:
A: Shares and
voting rights
Class/type of Number of % of shares
sharesISIN shares and and voting
code (if voting rights
possible) rights
Direct(SMA Indirect(SMA Direct(SMA Indirect(SMA
9:5) 9:6 and 9:7) 9:5) 9:6 and 9:7)
FI4000330972 0 5,145,387 0 6.56 %
Click here to Click here Click here Click here Click here
enter text. to enter to enter to enter to enter
text. text. text. text.
Click here to Click here Click here Click here Click here
enter text. to enter to enter to enter to enter
text. text. text. text.
SUBTOTAL A Click here Click here
to enter to enter
text. text.

Information in
relation to the
person subject to
the notification
obligation ☐
Person subject to
the notification
obligation is not
controlled by any
natural person or
legal entity and
does not control
any other
undertaking(s)
holding directly
or indirectly an
interest in the
(underlying)
issuer.☒ Full
chain of
controlled
undertakings
through which the
voting rights
and/or the
financial
instruments are
effectively held
starting with the
ultimate
controlling
natural person or
legal entity:
Name % of shares % of shares and voting rights Total of
and voting through financial instruments both
rights
Mandatum Oyj 0 0 0
Mandatum Holding 0 0 0
Oy
Mandatum 5.49 % 0 5.49 %
Henkivakuutusyhtiö
Mandatum Asset 0 0 0
Management Oy
Mandatum Fund Under 5 % 0 Under 5 %
Management S.A.

The notification of major shareholdings is based on the law 163/2024, in accordance with which a shareholder of a First North company is required to notify certain major shareholdings within two months from the entry into force of the law, in the event that the holding of shares or votes on the entry into force of the law on April 19, 2024 was at least 5 % and it had not been made public prior. The numbers and percentages in the notification are current as of the date of the entry into force of the law 163/2024 which was April 19,2024.

Nanoform Finland Plc

For further information, please contact:

Peter Hänninen, General Counsel

peter.hanninen@nanoform.com,+358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com,+46 7686 650 11

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Carnegie Investment Bank AB (publ), +46 8-588 68 570. For more information, please visit www.nanoform.com.